Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jane Elizabeth Rogers

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7275-7008; OpenAlex author ID A5013187820. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s12029-026-01601-z↗
  2. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Tri… Co-author DOI 10.1007/s12029-023-00930-7↗
  3. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  4. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Co-author DOI 10.21037/jgo-20-569↗
  5. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
  6. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. First author DOI 10.1016/j.pan.2020.01.005↗
  7. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. Co-author DOI 10.21037/jgo.2019.10.05↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shubham Pant · 7 shared papers, 2020–2026 · strength 1.07
  2. Jonathan D. Mizrahi · 6 shared papers, 2020–2026 · strength 0.90
  3. Robert A. Wolff · 6 shared papers, 2020–2023 · strength 0.71
  4. Milind M. Javle · 5 shared papers, 2020–2021 · strength 0.55
  5. Rachna T. Shroff · 4 shared papers, 2020–2021 · strength 0.44
  6. Michael James Overman · 4 shared papers, 2020–2021 · strength 0.43
  7. Gauri Rajani Varadhachary · 4 shared papers, 2020–2021 · strength 0.43
  8. Passant Shaker · 1 shared paper, 2026 · strength 0.36
  9. Kanwal P. S. Raghav · 3 shared papers, 2020–2021 · strength 0.32
  10. David R. Fogelman · 3 shared papers, 2020–2021 · strength 0.31
  11. Rishi Surana · 2 shared papers, 2021–2023 · strength 0.29
  12. Chirayu Mohindroo · 2 shared papers, 2020–2021 · strength 0.20
  13. Florencia M. McAllister · 2 shared papers, 2020–2021 · strength 0.20
  14. Funda Meric-Bernstam · 1 shared paper, 2023 · strength 0.17
  15. Jordi Ahnert Rodon · 1 shared paper, 2023 · strength 0.17
  16. Brandon George Smaglo · 1 shared paper, 2023 · strength 0.17
  17. Vivek Subbiah · 1 shared paper, 2023 · strength 0.17
  18. Timothy Anthony Yap · 1 shared paper, 2023 · strength 0.17
  19. David S. Hong · 1 shared paper, 2023 · strength 0.17
  20. Aung Naing Pe · 1 shared paper, 2023 · strength 0.17
  21. Graciela M. Nogueras‐González · 1 shared paper, 2021 · strength 0.12
  22. Matthew H. G. Katz · 1 shared paper, 2021 · strength 0.10
  23. Laura R. Prakash · 1 shared paper, 2021 · strength 0.10
  24. Michael P. Kim · 1 shared paper, 2021 · strength 0.10
  25. Michael T. Lotze · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.